Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies
Abstracts Cancer survivors are at significant risk of cardiovascular (CV) morbidity and
mortality; patients with hematologic malignancies have a higher rate of death due to heart …
mortality; patients with hematologic malignancies have a higher rate of death due to heart …
Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic malignant neoplasms: a meta-analysis
Importance The frequency and clinical phenotypes of cardiotoxic events in chimeric antigen
receptor (CAR) T-cell recipients remain poorly understood given that landmark approval …
receptor (CAR) T-cell recipients remain poorly understood given that landmark approval …
Cardiovascular toxicities associated with novel cellular immune therapies
Over the past decade, T-cell directed therapies, including chimeric antigen receptor T-cell
(CAR-T) and bispecific T-cell engager (BTE) therapy have reshaped the treatment of an …
(CAR-T) and bispecific T-cell engager (BTE) therapy have reshaped the treatment of an …
Cardiotoxicities of Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Antibodies
SZ Qamer, GM Miraglia, MJ Granville… - … Treatment Options in …, 2024 - Springer
Abstract Purpose of Review Chimeric antigen receptor T-cells (CAR-T) and bispecific
antibodies (BiTE) are novel therapies used to treat hematologic malignancies, lung cancer …
antibodies (BiTE) are novel therapies used to treat hematologic malignancies, lung cancer …
Cardiac adverse events after Chimeric Antigen Receptor (CAR) T cell therapies: an updated systematic review and meta-analysis
Purpose Chimeric antigen receptor (CAR) T-cell therapy is a new revolutionary method for
treating refractory or relapsed hematologic malignancies, CAR T-cell therapy has been …
treating refractory or relapsed hematologic malignancies, CAR T-cell therapy has been …
The cardiotoxic effects of CAR‐T cell therapy: An updated systematic review and meta‐analysis
RASV Mazetto, SON Monteiro… - European Journal of …, 2024 - Wiley Online Library
Background Chimeric antigen receptor T‐cell (CAR‐T) therapy has shown promise in
treating hematologic malignancies, yet its potential cardiotoxic effects require thorough …
treating hematologic malignancies, yet its potential cardiotoxic effects require thorough …
Guarding the Heart in an Era of “Tachy-CAR-T” The Rapid Proliferation of a Transformative Therapy
B Blue, M Alomar, FL Locke - Cardio Oncology, 2023 - jacc.org
In this issue of JACC: CardioOncology, Lefebvre et al 1 report the first single-center
prospective observational study designed to evaluate the cardiac events profile of patients …
prospective observational study designed to evaluate the cardiac events profile of patients …
[HTML][HTML] From the mechanism of action to clinical management: A review of cardiovascular toxicity in adult treated with CAR-T therapy
F Nunes, BM de Gusmão, FB Wiginesk… - … , Transfusion and Cell …, 2024 - Elsevier
Chimeric antigen receptor T-cell therapy represents an innovative approach to
immunotherapy and currently stands out, particularly for oncohematological patients …
immunotherapy and currently stands out, particularly for oncohematological patients …
Cardiovascular Events in Adult Patients Receiving CAR T-Cell Therapy in Real-World Clinical Settings: A Proportional Meta-Analysis
Background: The frequency and clinical phenotypes of cardiotoxic events in CAR T-cell
recipients remain poorly understood, since landmark approval trials typically excluded …
recipients remain poorly understood, since landmark approval trials typically excluded …